Clinical Trials
7 trialsNCT04172675 2026-02-24
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
Phase 2 Completed
NCT05375903 2026-01-14
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
Phase 1 Completed
NCT01697306 2025-01-30
The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer
A.O.U. Città della Salute e della Scienza
Phase 2 Completed
NCT02695771 2023-04-21
BIC
Corewell Health West
Phase 3 Completed
NCT02009332 2021-06-08
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Aadi Bioscience, Inc.
Phase 1/2 Completed
NCT00192049 2007-05-17
A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00191711 2007-01-26
Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.
Eli Lilly and Company
Phase 2 Completed